Go to the list of all blogs
Allana's Avatar
published in Blogs
Jan 15, 2019
Healthcare Stocks to Remain Strong in 2019: Reuters

Healthcare Stocks to Remain Strong in 2019: Reuters

In last year's volatile market, healthcare remained a strong investment for those seeking growth. As we start 2019, healthcare remains a favorite sector of Wall Street, according to a report in Reuters

Supporters say the healthcare sector has reasonable valuations, strong balance sheets and dividend payments. For 2019, healthcare companies in the S&P 500 are expected to increase earnings by 7.5 percent, ahead of the 6.3 percent growth estimated for S&P 500 companies overall, according to IBES data from Refinitiv.

Related Ticker: IYH

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


Momentum Indicator for IYH turns negative, indicating new downward trend

IYH saw its Momentum Indicator move below the 0 level on September 04, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned negative. In 70 of the 88 cases, the stock moved further down in the following days. The odds of a decline are at 80%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for IYH moved out of overbought territory on August 26, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 23 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 77%.

The Moving Average Convergence Divergence Histogram (MACD) for IYH turned negative on August 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 37 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 77%.

IYH moved below its 50-day moving average on September 10, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IYH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a +1.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where IYH advanced for three days, in 253 of 318 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

IYH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 206 of 250 cases where IYH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), Unitedhealth Group (NYSE:UNH), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Abbott Laboratories (NYSE:ABT), Pfizer (NYSE:PFE), Intuitive Surgical (NASDAQ:ISRG).

Industry description

The investment seeks to track the investment results of the Russell 1000 Health Care RIC 22.5/45 Capped Index composed of U.S. equities in the healthcare sector. The fund generally will invest at least 80% of its assets in the component securities of its underlying index. The underlying index measures the performance of the healthcare sector of the U.S. equity market. The fund is non-diversified.

Market Cap

The average market capitalization across the iShares US Healthcare ETF ETF is 84.11B. The market cap for tickers in the group ranges from 807.82M to 994.49B. LLY holds the highest valuation in this group at 994.49B. The lowest valued company is QDEL at 807.82M.

High and low price notable news

The average weekly price growth across all stocks in the iShares US Healthcare ETF ETF was -3%. For the same ETF, the average monthly price growth was -2%, and the average quarterly price growth was 12%. ROIV experienced the highest price growth at 17%, while COO experienced the biggest fall at -23%.

Volume

The average weekly volume growth across all stocks in the iShares US Healthcare ETF ETF was 19%. For the same stocks of the ETF, the average monthly volume growth was -3% and the average quarterly volume growth was -19%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 47
P/E Growth Rating: 49
Price Growth Rating: 43
SMR Rating: 66
Profit Risk Rating: 77
Seasonality Score: -25 (-100 ... +100)
View a ticker or compare two or three
IYH
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Category Health

Profile
Details
Category
Health
Address
iShares Trust400 Howard StreetSan Francisco
Phone
415-670-2000
Web
www.ishares.com
Interact to see
Advertisement
IGV has rallied about 8–9% in the last 6 trading days, while SOXX has dropped about 8%, giving software a +16.6 percentage‑point edge—the largest 6‑day software‑over‑semi outperformance ever.[barchart]​ This comes right after software lagged semis by almost −15 percentage points into late January, the widest gap since 2008, and as hedge‑fund short exposure to U.S. software and services hit a record ~3.8% of market cap.
Crude’s explosive war‑driven spike faded on March 9 because the market suddenly started to price less extreme, shorter‑lived supply risk and more policy intervention, not a multi‑month shortage. WTI, which had briefly traded above 115–120 dollars on Iran‑war headlines and Strait of Hormuz fears, slid back toward the high‑80s as traders digested G7 reserve‑release talk, Trump’s comments about a “brief” war, and the reality that prices had run far ahead of fundamentals.
Shares of ARQ plunged approximately 27.50% in premarket trading on March 10, 2026, from a prior close of $3.20 to roughly $2.32. The primary catalyst was a deeply disappointing Q4 2025 earnings report, which revealed a net loss of $50.0 million for the quarter versus a net loss of $1.3 million in Q4 2024.
RAIL shares fell approximately 15% in premarket trading on March 10, 2026, following a steep after-hours reaction to disappointing Q4 2025 earnings results released after the close on March 9. The primary catalyst was a significant revenue miss: Q4 revenue came in at $125.6 million, well below consensus estimates near $144–$160 million, representing an 8.8% year-over-year decline.
ZVRA shares surged approximately +17.86% on March 10, 2026, driven by a blockbuster Q4 and full-year 2025 earnings report released before the market open. Primary catalyst: Q4 2025 EPS of $0.19 crushed the consensus estimate of $0.05 — a 280% beat — while revenue of $34.1 million exceeded forecasts by 21.57%.
LITE surged +14.73% on Monday, March 9, 2026, closing at $640.69 versus a prior close of $558.44 on March 6. The primary catalyst was the landmark $2 billion strategic investment by NVIDIA announced March 2, with the market continuing to price in its full implications following a brief post-announcement pullback.
Shares of BNTX fell approximately 22% on Tuesday, March 10, 2026, following a dual shock of disappointing full-year guidance and a surprise leadership upheaval. The primary catalyst was BioNTech's Q4 2025 earnings report, which included a 2026 revenue outlook of €2.0–€2.3 billion — well below analyst consensus and signaling continued pressure from declining COVID-19 vaccine demand.
CNC shares fell approximately 10% during Tuesday's session, extending a prolonged selloff in the managed care sector. The primary catalyst is intensifying investor concern over federal Medicaid and ACA funding cuts tied to the "One Big Beautiful Bill Act" (OBBBA), which threatens to shrink the government-sponsored insurance pools that Centene depends on for the majority of its revenue.
Technology recently peaked near 35% of the S&P 500 and has slipped over the last year, while Energy plus Materials remain near historically low combined weight at roughly 6%, which suggests the gap is still unusually wide.
Average daily equity purchases by retail investors on S&P 500 down days in 2026 are at the highest level on record, running about 100% above the peak intensity seen during the 2021 meme‑stock boom.
Over the past two weeks, PLTR has climbed from roughly the high‑130s to the mid‑150s, a gain of about 12–14%, with a series of strong up days between March 2 and March 6.
AVAV shares dropped approximately 10% in premarket trading on March 11, 2026, following a disappointing Q3 fiscal 2026 earnings report released after the prior session's close. Q3 revenue of $408.0 million came in far below analyst consensus of approximately $475–$488 million, representing a massive top-line miss.
KOS shares are down approximately 20% in premarket trading on March 11, 2026, having shed roughly 20.31% across the last two sessions (Tuesday close and premarket Wednesday). The primary catalyst is Kosmos Energy's announcement of a massive $185.25 million public equity offering priced at $1.90 per share — a steep discount to recent trading levels.
NBIS shares surged approximately +10% in premarket trading on March 11, 2026, from a prior close of $96.32. The primary catalyst is the imminent addition of Nebius Group to the Bloomberg 500 (B500) Index, effective prior to the open of trading on Thursday, March 12, 2026.
ORCL shares surged approximately +10.49% in Wednesday's premarket session, trading around $165.07 versus Tuesday's closing price of $149.40. The primary catalyst is Oracle's Q3 FY2026 earnings beat, with adjusted EPS of $1.79 vs. the $1.70 consensus estimate, and revenue of $17.2 billion topping the $16.92 billion forecast.
Shares of AngloGold Ashanti plc (AU) are down approximately 5.00% in early trading on March 11, 2026, falling from a prior close of $108.26 to around $102.85. The primary driver is a renewed pullback in gold prices, which has weighed heavily on gold mining equities across the board.
HMY shares are trading down approximately 13% in early session trading on March 11, 2026, following the release of the company's H1 FY26 interim results. Revenue of R44.4 billion (~US$2.6 billion) missed analyst consensus estimates of R47.56 billion, a significant shortfall that spooked investors.
FICO fell over 9% today, extending a multi‑week downtrend that has already knocked the stock more than 7% lower since its last earnings update. The decline comes despite strong recent financial results, including double‑digit revenue growth, expanding margins, and repeated earnings beats.
RERE fell roughly 10% today, giving back a portion of its strong gains over the past year and month, as traders reacted to fresh earnings and guidance. The company delivered robust Q4 2025 results, with revenue growth near 30% year over year and earnings per share ahead of consensus estimates, underscoring continued operational momentum.
Top hedge funds like Millennium, Citadel, and Bridgewater showed limited direct accumulation of penny stocks in Q4 2025 13F filings, but rotations into biotech, energy, and defense sectors highlight indirect interest in low-priced plays under $5. New entries and increased positions focused on volatile sectors like biotech (e.g., ABCL) and energy (e.g., AMPY), with full exits from overvalued names signaling a hunt for undervalued pennies amid market uncertainty.